HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19

Astbury, Stuart, Reynolds, Catherine J, Butler, David K, Munoz‐Sandoval, Diana C, Lin, Kai‐Min, Pieper, Franziska P, Otter, Ashley, Kouraki, Afroditi, Cusin, Lola, Nightingale, Jessica, and others. (2022) HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19. Immunology, . ISSN 0019-2805. E-ISSN 1365-2567. (doi:10.1111/imm.13450) (KAR id:93195)

PDF Author's Accepted Manuscript Language: English
Download this file (PDF/10MB)	Preview
Request a format suitable for use with assistive technology e.g. a screenreader
Official URL: https://doi.org/10.1111/imm.13450

Abstract

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection, to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variation. Human leukocyte antigen (HLA) polymorphisms may influence immune response and disease outcome. We investigated the association of HLAII alleles with case definition symptomatic COVID-19, virus-specific antibody and T cell immunity. 1,364 UK healthcare workers (HCW) were recruited during the first U.K. SARS-CoV-2 wave and analyzed longitudinally, encompassing regular PCR screening for infection, symptom reporting, imputation of HLAII genotype and analysis for antibody and T cell responses to nucleoprotein (N) and spike (S). Of 272 (20%) HCW who seroconverted, the presence of HLA-DRB1*13:02 was associated with a 6.7-fold increased risk of case definition symptomatic COVID-19. In terms of immune responsiveness, HLA-DRB1*15:02 was associated with lower nucleocapsid T cell responses. There was no association between DRB1 alleles and anti-spike antibody titres after two COVID vaccine doses. However, HLA DRB1*15:01 was associated with increased spike T cell responses following both first and second dose vaccination.

Item Type:	Article
DOI/Identification number:	10.1111/imm.13450
Additional information:	This paper has COVIDsortium Investigators as an author and Nigel Temperton belongs to this group. Please see the acknowledgements section of the PDF paper.
Uncontrolled keywords:	COVID-19; HLA; immunogenetics; SARS-CoV-2; T cell immunity; vaccine
Subjects:	Q Science > QR Microbiology > QR355 Virology
Divisions:	Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User:	Nigel Temperton
Date Deposited:	15 Feb 2022 08:28 UTC
Last Modified:	05 Nov 2024 12:58 UTC
Resource URI:	https://kar.kent.ac.uk/id/eprint/93195 (The current URI for this page, for reference purposes)

University of Kent Author Information

Depositors only (login required):

Altmetric

Download Statistics

Total unique views for this document in KAR since July 2020. For more details click on the image.